Sanjivani Paranteral Board Approves Warrants Issue Worth ₹7.37 Crore

MUMBAI — Sanjivani Paranteral Limited, a Mumbai-headquartered pharmaceutical company, announced on July 23, 2026, that its Board of Directors approved the issuance and allotment of up to 500,000 fully convertible warrants. The capital raise, aggregating up to ₹7,36,95,000 (INR 7.37 crore), will be conducted on a preferential basis to an entity belonging to the promoter category.

The decision was made during a board meeting held between 6:30 P.M. and 7:50 P.M. IST on Thursday, in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The fresh equity infusion is intended to strengthen the company’s capitalization and support its operational expansion plans as it expands its footprint in the parenteral and health product segments.

Terms and Pricing of Preferential Issue

Under the approved structure, each warrant is priced at ₹147.39. The pricing was determined by the company's Board of Directors in alignment with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

According to regulatory filings submitted to BSE Limited:

• Proposed Allottee: Mr. Ashwani Khemka, belonging to the Promoter category.

• Conversion Option: Each warrant can be converted into one fully paid-up equity share of face value ₹10 within 18 months from the date of allotment in one or more tranches.

• Relevant Date: Thursday, July 23, 2026, was fixed as the relevant date for determining the minimum issue price under SEBI guidelines.

• Impact on Promoter Holding: Ashwani Khemka currently holds 36,70,117 equity shares, representing 29.88% of the equity share capital. Post-conversion of all 500,000 warrants, his holding will rise to 41,70,117 equity shares, bringing his stake to 32.62%.

Any warrants left unconverted after the maximum period of 18 months from the date of allotment will lapse, with the initial subscription funds paid standing forfeited to the company.

Related Party Transactions & Postal Ballot

In addition to the warrant issuance, the Board considered and approved a material related party transaction between Sanjivani Paranteral Limited and its subsidiary, SPL Infusion Private Limited. The approval is granted pursuant to Regulation 23 of SEBI LODR Regulations.

Both the preferential issue of convertible warrants and the related party transactions remain subject to the approval of the company's shareholders. To obtain shareholder consent, the board authorized the issuance of a Notice of Postal Ballot.

Official Sources Section

According to official disclosures filed with BSE Limited under Scrip Code 531569:

• The outcome of the Board Meeting held on July 23, 2026, was signed by Ravikumar Venkatramuloo Bogam, Company Secretary Cum Compliance Officer.

• Regulatory compliance is aligned with SEBI Listing Regulations, Chapter V of SEBI ICDR Regulations, and the Companies Act, 2013.

Quote Section

"According to official regulatory filings, the Board of Directors approved the issuance of up to 5,00,000 warrants at ₹147.39 per warrant to Mr. Ashwani Khemka on a preferential basis, subject to shareholder approval."

Why It Matters

The capital infusion provides Sanjivani Paranteral Limited with long-term equity capital to support capital expenditures and working capital requirements. For retail shareholders and market participants, the transaction demonstrates ongoing promoter commitment and increases promoter skin-in-the-game from 29.88% to 32.62% post-conversion. However, full conversion of warrants will result in equity dilution for non-promoter shareholders across the 18-month tenure.

Key Facts at a Glance

• Total Capital Raised: Up to ₹7,36,95,000 (INR 7.37 Crore).

• Total Warrants Issued: Up to 500,000 fully convertible warrants.

• Issue Price: ₹147.39 per warrant.

• Allottee: Mr. Ashwani Khemka (Promoter).

• Promoter Stake Change: Increases from 29.88% to 32.62% post-conversion.

• Conversion Tenure: Up to 18 months from allotment date.

Frequently Asked Questions (FAQ)

What was approved by Sanjivani Paranteral's board on July 23, 2026?

The board approved the preferential issue of up to 500,000 fully convertible warrants at ₹147.39 each to promoter Mr. Ashwani Khemka, raising up to ₹7.37 crore, along with related party transactions with subsidiary SPL Infusion Private Limited.

Who is the proposed allottee for the convertible warrants?

Mr. Ashwani Khemka, who belongs to the promoter category of Sanjivani Paranteral Limited.

How long does the holder have to convert the warrants into equity shares?

The warrant holder has a maximum timeframe of 18 months from the date of allotment to convert the warrants into equity shares in one or more tranches.

Will shareholder approval be required for this transaction?

Yes, both the issuance of warrants on a preferential basis and the material related party transactions require approval from shareholders through a postal ballot process.

Source: BSE Limited Disclosure - Sanjivani Paranteral Limited Outcome of Board Meeting